Company: PRGO
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001585364-25-000122
Chunk: 112

Company: PERRIGO Co plc
Filing Date: 2025-08-06
Form: 10-Q
Item: Part II, Item 1
Chunk 112
---
ization$34.9 $47.0 $— $81.9 

35

Perrigo Company plc - Item 1Note 17

CSCACSCIUnallocatedTotalSix Months Ended June 29, 2024Net sales$1,278.3 $869.3 $— $2,147.5 Cost of sales935.0 460.1 — 1,395.1 Gross profit343.3 409.2 — 752.4 Gross margin 26.9 %47.1 %— %35.0 %Operating expensesDistribution26.7 22.8 — 49.5 Research and development31.3 27.0 — 58.4 Selling110.3 190.1 — 300.4 Administration71.4 79.2 105.9 256.4 Impairment charges— 34.1 — 34.1 Restructuring18.6 39.8 23.0 81.3 Other operating (income) expense, net— — 54.0 54.0 Total operating expenses258.3 393.0 182.9 834.1 Operating income (loss)$85.0 $16.2 $(182.9)$(81.7)Operating income (loss) %6.6 %1.9 %NM(3.8)%Interest expense, net87.1 Other (income) expense, net3.8 Income (loss) from continuing operations before income taxes$(172.6)CSCACSCIUnallocatedTotalSix Months Ended June 29, 2024Capital expenditures$39.8 $13.7 $— $53.5 Depreciation/amortization$68.1 $95.3 $— $163.3 (1) Amounts may not add or recalculate due to rounding. Percentages are based on actuals.

NOTE 18 - SUBSEQUENT EVENTS

DivestituresOn July 13, 2025, we entered into a binding agreement to sell our Dermacosmetics branded business in Northern Europe, the Netherlands and Poland (the "Dermacosmetics Business") to Kairos Bidco AB ("Kairos") for total consideration of up to €327 million